VAXXAS’ new needle-free
vaccine delivery system,
Nanopatch, has been awarded the
Best Venture Capital Investment at
the 2012 Vaccine Industry
Excellence Awards.
The Nanopatch was created by
Prof Mark Kendall and his team at
University of Queensland’s
Australian Institute for
Bioengineering and Nanotechnology,
and was made commercially viable
by a $15m investment in Vaxxas Pty
Ltd by OneVentures, Brandon
Capital Partners, the Medical
Research Commercialisation Fund,
and US-based HealthCare Ventures.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 18 Apr 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
